Dr. Ivana Magovcevic-Liebisch is Executive Vice President and Chief Business Officer of Ipsen. She was previously Senior Vice President and Head of Global Business Development at Teva Pharmaceuticals. In this capacity, Ivana was responsible for the execution of transactions identified by Teva’s R&D, Global Franchises and US Specialty teams, including the licensing of commercial products, drug candidates and technologies. Prior to Teva, Dr. Magovcevic-Liebisch held several senior positions at Dyax Corp., most recently as Executive Vice President and Chief Operating Officer. Prior to Dyax, Dr. Magovcevic-Liebisch was Director of Intellectual Property and Patent Counsel for Transkaryotic Therapies, Inc., Cambridge, MA.